Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 37Terminated 7Recruiting 5Withdrawn 2Unknown 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leiomyoma 1Colonic Neoplasms 1

Interventions

pembrolizumab 439Carboplatin 322Nivolumab 298Cyclophosphamide 286Specimen Handling 271Magnetic Resonance Spectroscopy 259Cisplatin 250Paclitaxel 249Radiotherapy 230Dexamethasone 184Biopsy 182Gemcitabine 180durvalumab 171atezolizumab 152Doxorubicin 141Rituximab 138Lenalidomide 136Ipilimumab 134Docetaxel 132Bevacizumab 132Radiation 121Capecitabine 120Oxaliplatin 116Etoposide 116Radiosurgery 113Fluorouracil 112Pemetrexed 109fludarabine 106venetoclax 102Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Tea × Clear all
NCT05364008 2026-03-23

FRIEND

Yale University

Phase 3 Active not recruiting
33 enrolled

Leiomyoma

NCT02891538 2025-09-04

Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients

The University of Texas Health Science Center at San Antonio

Phase EARLY_PHASE1 Active not recruiting
51 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡